by jlohrconsulting | Jul 30, 2025 | Uncategorized
Neurology. 2025 Aug 26;105(4):e213913. doi: 10.1212/WNL.0000000000213913. Epub 2025 Jul 28. ABSTRACT BACKGROUND AND OBJECTIVES: The prognostic significance and the benefits of antiseizure treatment for definite and possible status epilepticus (SE) after cardiac arrest...
by jlohrconsulting | Jul 30, 2025 | Uncategorized
CNS Drugs. 2025 Jul 29. doi: 10.1007/s40263-025-01197-1. Online ahead of print. ABSTRACT BACKGROUND: TV-46000 is a long-acting subcutaneous injectable formulation of risperidone approved for treatment of schizophrenia in adults. The aim of this post hoc safety...
by jlohrconsulting | Jul 30, 2025 | Uncategorized
Sci Rep. 2025 Jul 29;15(1):27537. doi: 10.1038/s41598-025-11952-5. ABSTRACT Mental health issues among high school students have become increasingly prominent. While physical activity is recognized for its ability to reduce symptoms of anxiety and depression, the...
by jlohrconsulting | Jul 30, 2025 | Uncategorized
J Immigr Minor Health. 2025 Jul 29. doi: 10.1007/s10903-025-01749-z. Online ahead of print. ABSTRACT Immigrants tend to exhibit better mental health compared to their U.S.-born counterparts, but this immigrant health advantage is not uniform across immigrant...
by jlohrconsulting | Jul 30, 2025 | Uncategorized
Dermatol Ther (Heidelb). 2025 Jul 29. doi: 10.1007/s13555-025-01497-w. Online ahead of print. ABSTRACT INTRODUCTION: Brodalumab, a human interleukin-17 receptor A antagonist, is approved for treating adults with moderate-to-severe plaque psoriasis who qualify for...
Recent Comments